Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesMapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
Clinical Cancer Research, 09/08/09
Mom CH et al. – Mapatumumab in combination with gemcitabine and cisplatin is safe and well tolerated at doses up to 30 mg/kg. Further studies on this combination are warranted.
Related Articles
Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program
Pediatric Blood & Cancer, 11/12/09
Relevance Score: 89%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
New agents for AML and MDS
Best Practice & Research: Clinical Haematology , 12/08/09
New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents
Biologics: targets & therapy, 12/08/09
Review: erythropoiesis-stimulating agents increase mortality in patients with cancer
Evidence-Based Medicine, 12/08/09
Sponsor
Article Search
Sponsor